Want to see ENLV full AI Analyst Report?
Top Page
Enlivex
(NASDAQ:ENLV)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.50
▲(64.47% Upside)
Action:Reiterated
Date:10/28/26
The score is held down primarily by weak financial performance (no revenue, ongoing operating losses and cash burn, and profits not translating to operating cash flow) and very bearish technicals (price well below major moving averages with weak momentum). A strong, low-debt balance sheet provides support, and the very low P/E looks optically attractive, but valuation is tempered by earnings-quality and cash-flow concerns.
Positive Factors
Clinical pipeline progress
Reaching 70% enrollment in a controlled Phase 2b study provides a meaningful development milestone for Allocetra and moves the program closer to efficacy validation. The FDA’s RMAT designation and defined data timeline could support regulatory momentum if results confirm earlier clinical findings.
Negative Factors
No commercial revenue
Persistent zero revenue confirms that Enlivex remains dependent on research progress rather than an operating commercial franchise. Without product sales, the company has limited internally generated funding and must rely on capital resources, making clinical delays or unsuccessful trials more consequential.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline progress
Reaching 70% enrollment in a controlled Phase 2b study provides a meaningful development milestone for Allocetra and moves the program closer to efficacy validation. The FDA’s RMAT designation and defined data timeline could support regulatory momentum if results confirm earlier clinical findings.
Read all positive factors
Enlivex (ENLV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.14M
Dividend YieldN/A
Average Volume (3M)1.85M
Price to Earnings (P/E)<0.1
Beta (1Y)0.55
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)9239.68
Shares Outstanding24,511,906
10 Day Avg. Volume587,948
30 Day Avg. Volume1,850,159
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap6.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-133.95
Enterprise Value/Ebitda-1.44
Forecast
1Y Price Target
$80.00Price Target Upside5163.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-18.4
Revenue Forecast (FY)N/A
Enlivex Business Overview & Revenue Model
Company Description
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-bas...
Enlivex Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
78
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -214.00K | -332.00K | -545.00K | -835.00K | -777.00K | -546.00K |
| EBITDA | -19.93M | -14.67M | -14.47M | -28.22M | -25.02M | -18.74M |
| Net Income | 4.11B | 1.24B | -15.01M | -29.07M | -31.06M | -14.47M |
Balance Sheet | ||||||
| Total Assets | 4.90B | 2.33B | 27.69M | 36.83M | 67.64M | 95.15M |
| Cash, Cash Equivalents and Short-Term Investments | 5.52M | 5.87M | 23.61M | 27.32M | 50.24M | 84.13M |
| Total Debt | 17.25M | 641.00K | 534.00K | 1.03M | 4.85M | 6.01M |
| Total Liabilities | 1.00B | 392.05M | 4.10M | 6.75M | 10.80M | 10.11M |
| Stockholders Equity | 3.90B | 1.93B | 23.59M | 30.08M | 56.84M | 85.04M |
Cash Flow | ||||||
| Free Cash Flow | -16.17M | -10.48M | -13.11M | -23.76M | -32.08M | -19.17M |
| Operating Cash Flow | -15.80M | -10.42M | -13.01M | -23.52M | -23.95M | -17.54M |
| Investing Cash Flow | -14.50M | -1.32M | 9.06M | -25.97M | 62.52M | -38.41M |
| Financing Cash Flow | 33.87M | 10.38M | 6.45M | 360.00K | 150.00K | 60.98M |
Enlivex Technical Analysis
Negative
1.52
Price Trends
11.51
Negative
52.21
Negative
141.52
Negative
Market Momentum
-2.97
Negative
14.40
Positive
19.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENLV, the sentiment is Negative. The current price of 1.52 is below the 20-day moving average (MA) of 3.98, below the 50-day MA of 11.51, and below the 200-day MA of 141.52, indicating a bearish trend. The MACD of -2.97 indicates Negative momentum. The RSI at 14.40 is Positive, neither overbought nor oversold. The STOCH value of 19.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENLV.
Enlivex Risk Analysis
Enlivex disclosed 70 risk factors in its most recent earnings report. Enlivex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enlivex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $15.02M | >-0.01 | -147.45% | ― | ― | ― | |
46 Neutral | $10.78M | -0.30 | -218.59% | ― | ― | 38.14% | |
45 Neutral | $4.14M | <0.01 | 211.00% | ― | ― | ― | |
44 Neutral | $13.04M | -0.84 | -748.08% | ― | ― | ― |
* Healthcare Sector Average
ENLV
Enlivex
2.61
-254.19
-98.98%
DARE
Daré Bioscience
0.68
-1.34
-66.34%
AKTX
Akari Therapeutics
9.20
-20.82
-69.35%
PASG
Passage Bio
3.33
-4.10
-55.18%
Enlivex Corporate Events
Enlivex Reaches 70% Enrollment in Phase 2b Allocetra Trial for Knee Osteoarthritis
Oct 28, 2026
On October 28, 2026, Enlivex announced that it has randomized 135 patients, out of a planned 182, in its global Phase 2b trial of Allocetra™ for moderate-to-severe age-related primary knee osteoarthritis in patients aged 64 and older. The do...
Enlivex Faces Nasdaq Delisting, Launches Appeal and 1-for-16 Reverse Split
Oct 27, 2026
On October 26, 2026, Enlivex received a delisting notification from Nasdaq after its ordinary shares failed to meet the $1.00 minimum bid price for 30 consecutive business days prior to October 22, 2026. Because the company had already executed a ...
Enlivex to Implement 1-for-16 Reverse Share Split Effective October 27, 2026
Oct 22, 2026
On October 22, 2026, Enlivex held an Extraordinary General Meeting in Israel at which shareholders approved a reverse share split and authorized the board to set the final ratio. The meeting also granted the board authority to implement additional...
Enlivex Slashes Costs and Workforce to Prioritize Phase 2b Knee Osteoarthritis Trial
Oct 19, 2026
On October 19, 2026, Enlivex announced an immediate cost reduction plan that winds down all non-clinical RD to concentrate resources on its global Phase 2b trial of Allocetra™ in moderate-to-severe age-related primary knee osteoarthritis. Th...
Enlivex Calls October 14 Extraordinary Meeting to Approve 1-for-16 Reverse Share Split
Sep 29, 2026
On September 29, 2026, Enlivex announced it will convene an Extraordinary General Meeting of shareholders on October 14, 2026, at its Nes Ziona headquarters in Israel. The meeting will ask investors to approve a 1-for-16 reverse share split of the...
Enlivex Posts Massive H1 2026 Profit on Surging Digital Asset Holdings
Sep 25, 2026
On September 25, 2026, Enlivex filed a Form 6-K with the U.S. Securities and Exchange Commission, furnishing unaudited condensed consolidated financial statements for the three- and six-month periods ended June 30, 2026 and 2025, along with an ope...
Enlivex Drops RAIN-Token Financing Deal, Halts Planned Private Placement
Sep 22, 2026
Enlivex Ltd., a Nasdaq-listed longevity-focused biotech, is developing Allocetra™, an advanced immunotherapy for age-related inflammatory diseases such as osteoarthritis, while simultaneously managing a prediction markets-driven digital asse...
Enlivex Restructures $19.2 Million Convertible Note With Lind, Easing Default Risk
Aug 11, 2026
On August 11, 2026, Enlivex Ltd. amended its senior secured convertible promissory note originally issued on March 23, 2026 to Lind Global Asset Management XIV LLC, adjusting key terms to address a prior default risk linked to the company’s ...
Enlivex Highlights 622% Surge in Rain Protocol Trading Volume to $860 Million
Jul 30, 2026
Enlivex Ltd., a longevity-focused biotech powered by a prediction markets treasury, reported a sharp increase in trading activity on the Rain protocol as part of its digital-asset strategy. The company’s dual focus on clinical-stage immunoth...
Enlivex to Brief Investors on Private Placement, Rain Treasury Strategy and Allocetra RMAT Milestone
Jul 29, 2026
On July 29, 2026, Enlivex announced that its management will host a live investor webinar on July 30, 2026, to discuss its recently disclosed private placement, capital allocation plans, and long-term treasury strategy anchored in the Rain protoco...
Enlivex Strikes $400 Million Private Placement Tied to RAIN Token Treasury Strategy
Jul 28, 2026
On July 27, 2026, Enlivex Ltd. signed a securities purchase agreement with the Rain Foundation, an existing institutional shareholder that manages the RAIN token ecosystem, for a $400 million private placement of ordinary shares or pre-funded warr...
Enlivex Secures $400 Million Premium-Priced Private Placement Backed by RAIN Tokens
Jul 28, 2026
On July 28, 2026, Enlivex announced it had entered a securities purchase agreement for a $400 million private placement of ordinary shares or equivalents with a single institutional investor, priced at $5.00 per share for subscriptions in U.S. dol...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.